Showing results (211-220 of 234) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA TrialAurore Perrot, Thierry Facon, Torben Plesner, et al.
The Lancet. Oncology|February 17, 2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 studyAlison J Moskowitz, Heiko Schöder, Joachim Yahalom, et al.
Haematologica|June 11, 2026
Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1Deeksha Vishwamitra, Sheri Skerget, Diana Cortes-Selva, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 StudyThomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
FEMS Microbiology Reviews|October 4, 2024
Biodiversity of microorganisms in the Baltic Sea: the power of novel methods in the identification of marine microbesHanna Mazur-Marzec, Anders F Andersson, Agata Błaszczyk, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2011
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantationDoris M Ponce, Junting Zheng, Anne Marie Gonzales, et al.
Blood|April 24, 2024
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 studyDiana Cortes-Selva, Tatiana Perova, Sheri Skerget, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Pageof 24